Search Tag: breast cancer
2025 30 Jun
In a strategic move to improve patient outcomes in breast cancer, Affidea , a leading pan-European provider of community-based polyclinics, specialist services and advanced diagnostics, is proud to announce that has selected b-rayZ, a leader in AI-powered breast imaging solutions, as its preferred AI partner for breast imaging. Breast cancer...Read more
2025 30 Jun
In a strategic move to improve patient outcomes in breast cancer, Affidea , a leading pan-European provider of community-based polyclinics, specialist services and advanced diagnostics, is proud to announce that has selected b-rayZ, a leader in AI-powered breast imaging solutions, as its preferred AI partner for breast imaging. Breast cancer...Read more
2025 30 Jun
In a strategic move to improve patient outcomes in breast cancer, Affidea , a leading pan-European provider of community-based polyclinics, specialist services and advanced diagnostics, is proud to announce that has selected b-rayZ, a leader in AI-powered breast imaging solutions, as its preferred AI partner for breast imaging. Breast cancer...Read more
2025 20 Jun
Magnetic resonance imaging (MRI) remains the most sensitive tool for breast cancer detection, particularly in women with dense breast tissue. Its growing application spans screening high-risk populations, staging malignancies and assessing treatment response. However, long acquisition times and susceptibility to image artefacts have limited broader...Read more
2025 20 Jun
Magnetic resonance imaging (MRI) remains the most sensitive tool for breast cancer detection, particularly in women with dense breast tissue. Its growing application spans screening high-risk populations, staging malignancies and assessing treatment response. However, long acquisition times and susceptibility to image artefacts have limited broader...Read more
2025 30 May
Affidea has acquired Uroviva, Switzerland’s top urology network, nearly doubling its size and expanding integrated oncology services. The move strengthens Affidea’s breast and prostate cancer pathways, combining diagnostics, treatment and monitoring. Uroviva’s expertise and advanced technologies will support a seamless, patient-centred care model...Read more
2025 30 May
Affidea has acquired Uroviva, Switzerland’s top urology network, nearly doubling its size and expanding integrated oncology services. The move strengthens Affidea’s breast and prostate cancer pathways, combining diagnostics, treatment and monitoring. Uroviva’s expertise and advanced technologies will support a seamless, patient-centred care model...Read more
2025 22 May
Breast cancer is the most common malignancy among women worldwide, with early detection playing a pivotal role in improving survival outcomes. Mammography remains the gold standard for breast cancer screening, but its interpretation is fraught with challenges, including variability in radiologist expertise and the risk of diagnostic error. Artificial...Read more
2025 22 May
Breast cancer is the most common malignancy among women worldwide, with early detection playing a pivotal role in improving survival outcomes. Mammography remains the gold standard for breast cancer screening, but its interpretation is fraught with challenges, including variability in radiologist expertise and the risk of diagnostic error. Artificial...Read more
2025 22 May
Breast cancer is the most common malignancy among women worldwide, with early detection playing a pivotal role in improving survival outcomes. Mammography remains the gold standard for breast cancer screening, but its interpretation is fraught with challenges, including variability in radiologist expertise and the risk of diagnostic error. Artificial...Read more
2025 03 Apr
Strategic acquisition creates a leading oncology platform in Switzerland, with super-specialisation in breast and prostate cancer and an integrated care pathway Affidea Group, a leading pan-European provider of specialist healthcare services including cancer care, advanced diagnostic imaging and community-based polyclinics, today announced...Read more
2025 04 Feb
Affidea Group, the pan-European provider of specialist healthcare services, including cancer care, advanced diagnostic imaging and community-based polyclinics , announced today the acquisition of Instituts für histologische und zytologische Diagnostik AG, in Switzerland. This acquisition adds two high-quality pathology laboratories...Read more
2024 25 Aug
Breast cancer (BC) remains the most prevalent malignancy among women globally. The classification and accurate identification of human epidermal growth factor receptor 2 (HER2) status are critical for determining appropriate treatment plans, particularly for targeted therapies. Traditionally, HER2 status is assessed through invasive methods such...Read more
2024 06 Jun
Radial scars are abnormal growths in the breast tissue with a characteristic appearance on histopathology. They are increasingly being detected due to improved imaging techniques. Historically, they were often surgically removed due to concerns about potential cancer risk, but recent studies show variable rates of cancer upstaging following surgery....Read more
2024 29 Apr
Hologic, Inc., a global leader in women’s health, today announced that it signed a definitive agreement to acquire Endomagnetics Ltd (Endomag®), a privately held developer of breast cancer surgery technologies, for approximately $310 million, subject to working capital and other customary closing adjustments. “Endomag’s suite of solutions...Read more
2024 29 Apr
Hologic, Inc., a global leader in women’s health, today announced that it signed a definitive agreement to acquire Endomagnetics Ltd (Endomag®), a privately held developer of breast cancer surgery technologies, for approximately $310 million, subject to working capital and other customary closing adjustments. “Endomag’s suite of solutions...Read more
2024 29 Jan
A groundbreaking study led by Dr Dooman Arefan from the University of Pittsburgh has unveiled a promising method for predicting breast cancer recurrence risk. The research, published in Radiology , sheds light on how quantitative background parenchymal enhancement (BPE) measurements at dynamic contrast-enhanced MRI (DCE-MRI) could predict the...Read more
2024 29 Jan
A groundbreaking study led by Dr Dooman Arefan from the University of Pittsburgh has unveiled a promising method for predicting breast cancer recurrence risk. The research, published in Radiology , sheds light on how quantitative background parenchymal enhancement (BPE) measurements at dynamic contrast-enhanced MRI (DCE-MRI) could predict the...Read more
2024 22 Jan
b-rayZ, Swiss innovator in AI-powered medical imaging solution s, proudly announces the receipt of the CE mark for the groundbreaking DANAI technology. Seamlessly integrated into the comprehensive breast diagnostic suites, b-box plus, DANAI empowers breast cancer detection, density assessment and quality-controlled breast positioning. DANAI marks...Read more
2024 22 Jan
b-rayZ, Swiss innovator in AI-powered medical imaging solution s, proudly announces the receipt of the CE mark for the groundbreaking DANAI technology. Seamlessly integrated into the comprehensive breast diagnostic suites, b-box plus, DANAI empowers breast cancer detection, density assessment and quality-controlled breast positioning. DANAI marks...Read more
2024 22 Jan
b-rayZ, Swiss innovator in AI-powered medical imaging solution s, proudly announces the receipt of the CE mark for the groundbreaking DANAI technology. Seamlessly integrated into the comprehensive breast diagnostic suites, b-box plus, DANAI empowers breast cancer detection, density assessment and quality-controlled breast positioning. DANAI marks...Read more
2023 03 Nov
According to a new study, presented at the ACS Clinical Congress 2023, researchers have created an AI-driven tool for calculating the long-term survival prospects of recently diagnosed cancer patients. Estimating survival rates for patients with cancer normally depends on their cancer stage. However, numerous other factors can influence a...Read more
2023 11 Oct
A recent survey was conducted among breast radiologists to investigate the common factors that impact workplace satisfaction and the chances that breast radiologists leave their jobs. Members of the Society of Breast Imaging were surveyed about workplace satisfaction, with radiologists specifying recent departures from or contemplation of leaving...Read more
2023 30 Aug
The invitation proved too momentous to pass up. It arrived as I reached my third decade in academic medicine, including years of serving as Director of Breast Imaging for Johns Hopkins Medicine. During this entire time, it was a privilege to help thousands of women – and their families – navigate their journeys against breast cancer. ...Read more
2023 15 May
A recent study suggests that the more time it takes for breast density to decrease, the higher the chance a woman could develop breast cancer. In the study published in JAMA Oncology, the team used a mathematical model to monitor changes in breast density across a 10-year period in almost 1,000 women. The study revealed the association between...Read more
2023 09 May
As a leader in women’s health, Hologic knows that increasing access to breast cancer screening is critical to detecting cancer earlier and saving lives. We commend the U.S. Preventive Services Task Force (USPSTF) for changing their draft guidelines to recommend that women begin screening at age 40. Lowering the age for initial screening to 40...Read more
2023 09 May
As a leader in women’s health, Hologic knows that increasing access to breast cancer screening is critical to detecting cancer earlier and saving lives. We commend the U.S. Preventive Services Task Force (USPSTF) for changing their draft guidelines to recommend that women begin screening at age 40. Lowering the age for initial screening to 40...Read more
2023 05 May
The American College of Radiology (ACR) have released new breast cancer screening guidelines, recommending earlier and more intensive screening for women at high-risk. The latest scientific evidence states that all women at higher-than-average risk should undergo risk assessment by age 25 to determine if MRI surveillance is required earlier than...Read more
2023 05 May
The American College of Radiology (ACR) have released new breast cancer screening guidelines, recommending earlier and more intensive screening for women at high-risk. The latest scientific evidence states that all women at higher-than-average risk should undergo risk assessment by age 25 to determine if MRI surveillance is required earlier than...Read more